Alecensa
Named-patient access overview. Alecensa is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Alecensa (alectinib) is Roche's second-generation ALK tyrosine kinase inhibitor for ALK-rearranged non-small cell lung cancer. It has held FDA approval since 2015 and now spans first-line metastatic, second-line post-crizotinib, and adjuvant post-resection settings. For Saudi Arabia patients whose treating oncologist has identified an ALK rearrangement and recommended alectinib, this page describes the Personal Importation Program pathway and what to expect.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Alecensa
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Alecensa is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Alecensa in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Alecensa
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.